Jade Biosciences (JBIO) Competitors

$23.36 -0.77 (-3.19%)

Closing price 04:00 PM Eastern

Extended Trading

$22.89 -0.47 (-2.01%)

As of 04:28 PM Eastern

JBIO vs. DNTH, CRNX, KNSA, AMRX, and MANE

Should you buy Jade Biosciences stock or one of its competitors? MarketBeat compares Jade Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jade Biosciences include Dianthus Therapeutics (DNTH), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals International (KNSA), Amneal Pharmaceuticals (AMRX), and MANE (MANE). These companies are all part of the "pharmaceutical products" industry.

How does Jade Biosciences compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Jade Biosciences had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for Jade Biosciences and 7 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.15 beat Jade Biosciences' score of -0.35 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Jade Biosciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Jade Biosciences	N/A	-51.34%	-47.32%

Jade Biosciences has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,309.00	-$162.34M	-$4.13	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 36.74%. Jade Biosciences has a consensus target price of $34.33, indicating a potential upside of 46.97%. Given Jade Biosciences' higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Jade Biosciences beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Crinetics Pharmaceuticals?

Jade Biosciences (NASDAQ:JBIO) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Jade Biosciences has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 16 more articles in the media than Jade Biosciences. MarketBeat recorded 29 mentions for Crinetics Pharmaceuticals and 13 mentions for Jade Biosciences. Crinetics Pharmaceuticals' average media sentiment score of -0.07 beat Jade Biosciences' score of -0.35 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Jade Biosciences has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Jade Biosciences has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Jade Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Crinetics Pharmaceuticals	$7.70M	503.51	-$465.32M	-$5.13	N/A

Jade Biosciences presently has a consensus target price of $34.33, suggesting a potential upside of 46.97%. Crinetics Pharmaceuticals has a consensus target price of $76.13, suggesting a potential upside of 107.03%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Crinetics Pharmaceuticals beats Jade Biosciences on 10 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Kiniksa Pharmaceuticals International?

Jade Biosciences (NASDAQ:JBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Jade Biosciences had 9 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for Jade Biosciences and 4 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.03 beat Jade Biosciences' score of -0.35 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Kiniksa Pharmaceuticals International	$677.56M	6.42	$59.01M	$0.90	62.79

Jade Biosciences has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Jade Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Jade Biosciences presently has a consensus target price of $34.33, suggesting a potential upside of 46.97%. Kiniksa Pharmaceuticals International has a consensus target price of $60.86, suggesting a potential upside of 7.69%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Jade Biosciences on 11 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Amneal Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 25.73%. Jade Biosciences has a consensus target price of $34.33, indicating a potential upside of 46.97%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Jade Biosciences had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Jade Biosciences and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.84 beat Jade Biosciences' score of -0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.24	$72.06M	$0.38	31.39
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Amneal Pharmaceuticals has a net margin of 4.01% compared to Jade Biosciences' net margin of 0.00%. Jade Biosciences' return on equity of -51.34% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Jade Biosciences	N/A	-51.34%	-47.32%

Summary

Amneal Pharmaceuticals beats Jade Biosciences on 9 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to MANE?

Jade Biosciences (NASDAQ:JBIO) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Jade Biosciences currently has a consensus target price of $34.33, indicating a potential upside of 46.97%. MANE has a consensus target price of $83.33, indicating a potential downside of 16.49%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Jade Biosciences had 9 more articles in the media than MANE. MarketBeat recorded 13 mentions for Jade Biosciences and 4 mentions for MANE. MANE's average media sentiment score of -0.28 beat Jade Biosciences' score of -0.35 indicating that MANE is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MANE	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
MANE	N/A	N/A	N/A	N/A	N/A

MANE's return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
MANE	N/A	N/A	N/A

Summary

Jade Biosciences beats MANE on 5 of the 8 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.15B	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-11.56	18.05	20.38	25.28
Price / Sales	N/A	284.22	542.54	73.29
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	3.89	6.73	9.81	6.91
Net Income	-$127.41M	$24.11M	$3.56B	$333.88M
7 Day Performance	-9.49%	4.11%	0.43%	0.16%
1 Month Performance	21.29%	-2.89%	-0.87%	1.90%
1 Year Performance	N/A	69.06%	36.28%	32.84%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	2.2505 of 5 stars	$23.36 -3.2%	$34.33 +47.0%	N/A	$1.15B	N/A	N/A	20	Analyst Revision Gap Down
DNTH Dianthus Therapeutics	3.0514 of 5 stars	$85.49 -5.5%	$117.82 +37.8%	+351.5%	$4.65B	$2.04M	N/A	80	Positive News Gap Down
CRNX Crinetics Pharmaceuticals	2.0369 of 5 stars	$43.58 +4.5%	$76.75 +76.1%	+22.4%	$4.59B	$7.70M	N/A	210	Analyst Revision
KNSA Kiniksa Pharmaceuticals International	3.6447 of 5 stars	$56.85 -2.4%	$60.86 +7.1%	+133.9%	$4.35B	$677.56M	63.16	220	Positive News
AMRX Amneal Pharmaceuticals	4.3588 of 5 stars	$13.71 +0.6%	$15.00 +9.4%	+66.4%	$4.31B	$3.02B	36.07	8,500	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. DNTH, CRNX, KNSA, AMRX, and MANE

How does Jade Biosciences compare to Dianthus Therapeutics?

Summary

How does Jade Biosciences compare to Crinetics Pharmaceuticals?

Summary

How does Jade Biosciences compare to Kiniksa Pharmaceuticals International?

Summary

How does Jade Biosciences compare to Amneal Pharmaceuticals?

Summary

How does Jade Biosciences compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. DNTH, CRNX, KNSA, AMRX, and MANE

How does Jade Biosciences compare to Dianthus Therapeutics?

Which has more risk & volatility, DNTH or JBIO?

Does the media favor DNTH or JBIO?

Do institutionals and insiders hold more shares of DNTH or JBIO?

Is DNTH or JBIO more profitable?

Which has preferable valuation & earnings, DNTH or JBIO?

Do analysts prefer DNTH or JBIO?

Summary

How does Jade Biosciences compare to Crinetics Pharmaceuticals?

Which has more risk & volatility, JBIO or CRNX?

Does the media favor JBIO or CRNX?

Do institutionals and insiders believe in JBIO or CRNX?

Is JBIO or CRNX more profitable?

Which has better earnings & valuation, JBIO or CRNX?

Do analysts rate JBIO or CRNX?

Summary

How does Jade Biosciences compare to Kiniksa Pharmaceuticals International?

Does the media favor JBIO or KNSA?

Which has better earnings & valuation, JBIO or KNSA?

Which has more risk & volatility, JBIO or KNSA?

Is JBIO or KNSA more profitable?

Do analysts rate JBIO or KNSA?

Do institutionals and insiders believe in JBIO or KNSA?

Summary

How does Jade Biosciences compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or JBIO?

Does the media refer more to AMRX or JBIO?

Do insiders & institutionals believe in AMRX or JBIO?

Which has more risk & volatility, AMRX or JBIO?

Which has stronger valuation & earnings, AMRX or JBIO?

Is AMRX or JBIO more profitable?

Summary

How does Jade Biosciences compare to MANE?

Do analysts prefer JBIO or MANE?

Does the media favor JBIO or MANE?

Which has higher valuation and earnings, JBIO or MANE?

Is JBIO or MANE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools